Dedipya Bhamidipati

Please check out this review of Emerging Tumor Agnostic Biomarkers! Grateful to have had @AliSchram as a mentor. I learned a lot from her insights as a PI on numerous clinical trials in the Early Drug Development clinic @MSKCancerCenter!

Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With #ProstateCancer. Co-authored by @drdedipya, and @thewonkologist. Read the full article. brnw.ch/21wXFW7 #pcsm

So happy to share that one of my publications came out in JCO yesterday! ➡️ascopubs.org/doi/10.1200/OP… I am grateful to @TheWonkologist for giving me this opportunity to shed a light on BMA overuse and underuse in mCSPC and MCRPC respectively!

@drtulsijose @BioAscend @hemeoncfellow Congratulations!!

Embracing #Motherhood during hemeonc fellowship training has been a special journey. Thank you @BioAscend for shipping the #risingstar award. This one is dedicated to my co-fellows at @hemeoncfellow for bringing #mentorship accessible to trainees across US.

@hsafaMD Excited to be applying to #HemeOnc fellowship this cycle! I’m Dedipya Bhamidipati—IM chief resident! Excited to connect with programs & applicants! 📄 AAMC ID: 15373622 #MedTwitter #Fellowship2026 #Oncology #Hematology

🚨 Fellowship Applicants 🚨 Visibility matters. Believe it or not, people have landed interviews by having a presence on X. Drop your intro post with info (or create one!) in the replies here. All specialties are welcome. I’ll amplify as many as I can by reposting you. My modest following is yours today. Repost this to help others find the thread. Let’s get you noticed.

BREAKING from @NEJM In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is : 🔘Noninferior to full-dose (5 mg BID) for VTE recurrence 🔘Lower bleeding risk (12.1% vs. 15.6%) 🔘Safer extended anticoagulation, same protection. #Thrombosis #cancer @OncoAlert @Cihan_Ay_MD DOI: 10.1056/NEJMoa2416112

De-escalation of ICI therapy in NSCLC through either a) lower dosing regiments, b) decreased frequency of administration or c) fixed duration of therapy. The economic benefits would revolutionize antibody use! Such a valuable read @JordiRemon and @BenjaminBesseMD!

@chadihc98 @UofUInternalMed @UtahIMCMRs @neerajaiims @umangtalking @maughanonc @Huntsman_GU @montypal @nsayeghmd @ggebraelmd @ziremozay @huntsmancancer @vinay_onc @GliceidaGalarza @DrChoueiri @carolinemilneMD @ReneeSaliby Congratulations!!

Thrilled to have matched @UofUInternalMed for my internal medicine residency training! Can't wait to get started! @UtahIMCMRs Grateful for the terrific support of my family, friends, and mentors @neerajaiims @umangtalking @maughanonc @Huntsman_GU ! #Match2025

Establishing nivo/AVD in elderly patients with classic Hodgkin’s lymphoma would transform the care of patients suffering from cHL above the age of 60 years! Congratulations @PallawiTorkaMD @PaolaGhione_MD @SantoshVardhana!! So blessed to have worked with you!

Learned a lot from Dr. Salles during my elective in Lymphoma clinics over the past month. I got to see very interesting patients, with even more exciting treatment plans! @MSKCancerCenter truly harbors the most insightful teachers. Thankful to @Efrat_Luttwak for this rotation!!!

Now available on pubmed! Results of the zenocutuzumab (Bizengri) basket trial in NRG1 fusion + solid tumors. This trial led to recent FDA approval in lung and pancreatic cancer. RNA seq is critical to identify these fusions. 🧬@NEJM pubmed.ncbi.nlm.nih.gov/39908431/

When you’re watching your Lymphoma attending casually drop ASH updates during your heme elective at the VA! Perfect timing!

@AnmolGoyalMD @ASTCT @CCF_IMCHIEFS @ccfhemonc Congratulations!!!

Less than a month to go, and this just made it sweeter. Excited to share with and learn from everyone at @ASTCT! @CCF_IMCHIEFS @ccfhemonc

Cancer statistics- 2025 👀 Some 🫁 cancer observations: 1. Continued nice decrease in LC incidence/death rates 2. BUT probably 1st time in history of cancer stats- more cases in women than men 3. AND finally we no longer can say - “lung cancer causes more deaths than prostate/breast/colon cancer combined”- amazing progress💪👏🎉 (Lung cancer- 124730- colon/breast/prostate- 130840) acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca…

@NicoleFleege It certainly is! Especially for a meaningful process which almost always does end up taking time!

@drdedipya Thank you, that is so kind! It always helps me to see realistic timelines for research 😊

Just submitted a 30 page manuscript (ie hours and hours of my life) on a project I dreamed about in the office of my mentor in November 2019. Research happens slowly & then all at once. Accepted or rejected, I just feel proud to have seen this one through. #MedTwitter #bcsm

Cancer Chemotherapy @Cancer_Cell

Adjuvant IO trials in muscle-invasive urothelial carcinoma: IMvigor010: Atezo DFS HR 0.89, OS HR 0.85. CheckMate 274: Nivo DFS HR 0.71, OS HR 0.76. AMBASSADOR: Pembro DFS HR 0.73, OS HR 0.98. #oncology #cancer #urothelialcarcinoma @OncoAlert @MattGalsky @tompowles1 @apolo_andrea @Uromigos

ADCs are among the most rapidly expanding treatment modalities in oncology, with 11 ADCs approved and >200 in active development. Here’s 10 facts to know to prepare for the rise of ADCs🧵